(833) 317-6278
Book a Demo
Alejandro Alonso
Gray shield icon
Is this you?
Claim your profile.

Alejandro Alonso

Video Editor

AS SEEN ON
formulascout.com

Preston's Summary

Alejandro Alonso is a Video Editor for the Cureus Journal of Medical Science. With a focus on motorsports, Alejandro covers various racing events and provides insights into the world of Formula 2, Formula 3, and other racing championships. His articles highlight the achievements, challenges, and aspirations of drivers and teams in the competitive racing industry.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

Coverage Attributes:

Beta
Event Coverage: 76 %
Announcement: 7 %
Expert Commentary: 3 %
Profile Feature: 3 %
Press Release: 1 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Formula 1
  • Formula 2
  • Racing
  • F3
  • Drivers

Pitching Insights

Alejandro Alonso's articles primarily cover sports events, particularly in the realm of Formula 1, Formula 2, and racing. Given his focus on event coverage, he is likely to be receptive to pitches offering exclusive insights or interviews with drivers and teams participating in upcoming races or those reflecting on recent events. Additionally, since Alejandro covers a wide range of racing categories and specific events within them, relevant pitches could include unique perspectives from drivers or insiders related to these competitions.

Considering that Alejandro does not have a specified geographic focus but covers international sporting events extensively, pitching stories involving drivers or developments from various parts of the world may be well-received.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Fatima Ahmed

Fatima Ahmed

Journalist
Publications
Her Campus FSU
Most recent topics
Not enough data
Morgan Holiday

Morgan Holiday

Content Writer
*****n@*************com
Publications
FormulaNerds Ltd.
Most recent topics
Not enough data
Abby Bathurst

Abby Bathurst

F2 and F3 Editor
***y@*************com
Publications
FormulaNerds Ltd.
Most recent topics
Not enough data
Ida Wood

Ida Wood

******od@*************com
Publications
formulascout.com, SportBusiness
Most recent topics
Not enough data
Megan White

Megan White

Journalist
*****w@****************.com
Publications
The Race
Most recent topics
Not enough data
Alejandro Alonso Lopez

Alejandro Alonso Lopez

Publications
formulascout.com
Most recent topics
Not enough data

Articles

Cureus Journal of Medical Science

Treatment Challenges of Acquired Thrombotic Thrombocytopenic Purpura in Pediatric Patients From a Low-Income Country

Treatment Challenges of Acquired Thrombotic Thrombocytopenic Purpura in Pediatric Patients From a Low-Income Country

By: Willy Nava Gutiérrez, Juan-Daniel Garza-Escobar, Adriana-Carolina Sandoval-González, César-Alejandro Alonso-Tellez, Willy Nava-Gutiérrez

This study presents a comprehensive analysis of two cases of acquired thrombotic thrombocytopenic purpura (aTTP) observed in pediatric patients from a low-income country. In the instances described, both patients underwent a treatment regimen involving plasma exchange and immunosuppressive therapy conducted without the use of caplacizumab. Caplacizumab, an approved drug for adults known for its limited availability and high cost, has exhibited efficacy in reducing response time and recurrence frequency in aTTP cases. This approach resulted in significant clinical improvement and eventual remission of symptoms in one of the cases. These cases underscore the urgent necessity for a more inclusive approach in national health programs and international treatment guidelines. Specifically, there is a call to expand the existing comprehensive treatment algorithms to accommodate countries lacking access to caplacizumab. This adaptation aims to ensure the availability of suitable and effective treatment options for aTTP patients in regions facing limited pharmaceutical accessibility.

© 2025 Intelligent Relations